Spectrum of activity:
|
Gram-positive
&
Gram-negative
|
Details of activity:
|
Active against Staphylococcus aureus, Streptococcus pyogenes, vancomycin-resistant Enterococcus faecium, Staphylococcus epidermidis, Escherichia coli, Enterobacter aerogenes, Acinetobacter baumannii, Klebsiella pneumoniae, Proteus mirabilis, Haemophilus influenzae, Pseudomonas aeruginosa, and Serratia marcescens
|
Description:
|
Synthetic compound; active and well tolerated when administered as topical gel treatment for impetigo in children
|
Institute where first reported:
|
NovaBay Pharmaceuticals, Inc.
|
Year first mentioned:
|
2011
|
Highest developmental phase:
|
Phase 2 (NCT01367314; NCT00781339; NCT01532336; NCT01877694; NCT01243125)
|
Development status:
|
Unknown
|
Reason Dropped:
|
No results posted after clinical trial completion
|